Jonathan Anderman's most recent trade in Compass Therapeutics Inc was a trade of 720,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Compass Therapeutics Inc | Jonathan Anderman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 720,000 | 720,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Jonathan Anderman | General Counsel | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 02 Jan 2026 | 150,000 | 171,000 | - | 5.2 | 775,500 | Common Stock |
| Compass Therapeutics Inc | Jonathan Anderman | Gen Counsel & Corporate Sec | Purchase of securities on an exchange or from another person at price $ 1.54 per share. | 07 Apr 2025 | 20,000 | 21,000 | - | 1.5 | 30,800 | Common Stock |
| Compass Therapeutics Inc | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 280,000 | 280,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | 13 Aug 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) |